Natera (NASDAQ:NTRA) presented new data from its Signatera molecular residual disease (MRD) test at the IASLC 2026 World Conference on Lung Cancer, including results from a 1,129-patient analysis in early-stage non-small cell lung cancer.
Natera (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and MEDSIR (Medica Scientia Innovation Research), a global leader in oncology research, today announced their collaboration on the MiRaDoR (NCT05708235) study.
Natera (NASDAQ:NTRA) announced a significant clinical breakthrough today, revealing that its pivotal Phase III ALTAIR trial successfully reached statistical significance following a reclassification of patient data.
Natera (NASDAQ:NTRA) said its Signatera test has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency for use in colorectal cancer in the adjuvant setting.
Natera (NASDAQ:TRA) has entered into a clinical collaboration with Diakonos Oncology to deploy its liquid biopsy technology to track patient responses during an active trial for an aggressive skin cancer therapy.
